DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Meta Expands AI Training With Employee Activity Tracking Tools 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
NEW YORK, March 23, 2017 -- Mid Atlantic Bio Angels (MABA) announces today that OneThree Biotech (OneThree), a New York-based company developing artificial intelligence technology to more rapidly identify drug targets and side effects, was named “Best in Show” at MABA's 1st Pitch Life Science event on March 13, 2017 at Weill Cornell Medical Center in New York City.
"Presenting at 1st Pitch was an amazing opportunity to obtain candid investor feedback, which will dramatically shape our business development going forward,” said Neel Madhukar, CEO of OneThree Biotech.“We left even more determined to use artificial intelligence to change the way drugs are discovered and developed. We were honored to have been selected as the 'Best in Show.'”
“OneThree’s unique technology has the potential to streamline the new drug approval process through early identification of potential delivery targets and side effects,” said David Broderick, partner at the law firm of McCarter & English, LLP.
OneThree Biotech is developing an artificial intelligence platform to more rapidly identify drug targets. Unlike other approaches, OneThree’s platform uses its novel algorithms to combine diverse data types beyond the molecular structure of the drug in question. This allows the platform to more accurately identify targets and side effects (up to 90 percent accuracy) with greater flexibility and speed.
About 1st Pitch Life Science
At a 1st Pitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company's presentation, business model and perceived viability in the market.
About MABA
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]
